Interferon-alpha restitutes the chemosensitivity in pancreatic cancer

Anticancer Research

Volumn 28, Issue 3 A, 2008, Pages 1499-1507

  Hoffmann, Katrin ^a   Mehrle, Stefan ^a   Schmidt, Jan ^a   Büchler, Markus W ^a   Märten, Angela ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Interferon alpha combination therapy; Multidrug resistance; Pancreatic cancer

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; P-GLYCOPROTEIN; PANCREATIC NEOPLASMS;

EID: 45949106276     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ghaneh P, Sultana A, Shore S, Stocken D and Neoptolemos J: The case for adjuvant chemotherapy in pancreatic cancer. Best Pract Res Clinic Gastroenterol 20(2): 383-401, 2006.
2. Tsai JY, Iannitti DA and Safran H: Combined modality therapy for pancreatic cancer. Semin Oncol 30(4 Suppl. 9): 71-79, 2003.
3. Goldstein D, Caroll S, Apte M and Keogh G: Modern management of pancreatic cancer. Intern Med J 34(8): 475-478, 2004.
4. König J, Hartel M, Nies AT, Martignoni ME, Guo J, Büchler MW et al: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic cancer. International Journal of Cancer 115(3): 359-367, 2004.
5. Lu Z, Kleeff J, Shrikande S, Zimmermann A, Korc M, Friess H et al: Expression of the Multidrug-Resistance 1 (MDR1) Gene and Prognosis in Human Pancreatic Cancer. Pancreas 21(3): 240-247, 2000.
6. Suwa H, Ohshio G, Arao S, Imamura T, Yamaki K,ManabeT et al: Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J Cancer Res 87(6): 641-649, 1996.
7. Picozzi VJ and Traverso LW: The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin N Am 13(4): 663-674, 2004.
8. Picozzi VJ, Kozarek RA and Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. American J Surg 185: 476-480, 2003.
9. Neoptolemos J, Stocken D, Friess H, Bassi C, Dunn J, Hickey H et al: The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiotherapy and chemotherapy in patients with resectable pancreatic cancer. N Engl J Med 350: 1200-1210, 2004.
10. Knaebel HP, Maerten A, Schmidt J, Hoffmann K, Seiler C, Lindel K et at Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic carcinoma - CapRI: study protocoll (ISRCTN62866759). BMC Cancer 5(1): 37, 2005.
11. Marrack P, Kappler J and Mitchell T: Type I interferons keep activated T cells alive. J Exp Med 189(3): 521-530, 1999.
12. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ and Julkunen I: Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 93(6): 1980-1991, 1999.
13. Ma JH, Patrut E, Schmidt J, Knaebel HP, Buchler MW and Marten A: Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol 11(10): 1521-1528, 2005.
14. Schmidt J, Patrut E and Ma JH: Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother 55(11): 1396-1405,2006.
15. Pfeffer LM, Dinarello CA, Williams BR, Borden EC, Bordens R, Walter MR et at Biological properties of recombinant alphainterferons: 40th anniversary of the discovery of interferons. Cancer Res 58: 2489-2499, 1998.
16. Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PW, Evans DB et at Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-ssociated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 9(5): 1858-1867, 2003.
17. Zhu I, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jager D et at Interferon-alpha in combination with chemotherapy has potent anti-angiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 31(1): 28-33, 2007.
18. Zhu I, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jäger D et at Interferon-alpha enhances anti-tumour effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. submitted to Eur J Immunol 2007.
19. Holsti LR, Mattson K, Niiranen A, Standertskiold-Nordenstam CG, Stenman S, Sovijarvi A et at Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 13: 1161-1166, 1987.
20. Kurzrock R, Talpaz M and Guttermann J: Interferons: Clinical Applications. Lippincott Philadelphia, pp. 34-37, 1991.
21. Kang Y and Perry RR: Effect of α-Interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 54: 2952-2958, 1994.
22. Takeuchi A, Kaneko S, Matsushita E, Urabe T, Shimoda A and Kobayashi K: Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines. J Gastroenterol 34: 351-358, 1999.
23. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP et at: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726, 1984.
24. Schneider C, Schmidt T, Ziske K, Tiemann K, Lee KM, Uhlinsky V et at Tumour suppression induced by macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 53(3): 355-361, 2004.
25. Hoffmann K, Bekeredjian R, Schmidt J, Büchler MW and Märten A: Modulation of multi-drug resistance by high affinity peptides in pancreatic cancer. submitted to Cancer Lett 2007.
26. Lockhart AC, Rothenberg ML and Berlin JD: Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 128: 1642-1654, 2005.
27. Frank MH and Pomer S: Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype. J Cancer Res Clin Oncol 125(2): 117-120, 1999.
28. Miracco C, Maellaro E, Pacenti L, Del BB, Valentini MA, Rubegni P et at Evaluation of MDR1, LRP, MRP, and topoisomerase IIalpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines. Int J Oncol 23(1): 213-220, 2003.
29. Manara MC, Serra M, Benini S, Picci P and Scotlandi K: Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 24(2): 365-372, 2004.
30. Kang Y and Perry RR: Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance. Cancer Res 53(13): 3040-3045, 1993.
31. Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G et at: Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 51(18): 4898-4902, 1991.
32. Arany I, Fleischmann CM, Tyring SK and Fleischmann WR: Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells. Biochem Biophys Res Commun 233(3): 678-680, 1997.
33. Taylor JL and Grossberg SE: The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 25(1 Suppl 1): 23-29, 1998.
34. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M et at Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88(5): 1747-1754, 1996.
35. Stein U, Walther W and Shoemaker RH: Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 88(19): 1383-1392, 1996.
36. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Ill W and Dantzig AH: The mutidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosporylted metabolites. Mol Cancer Ther 4(5): 855-863, 2005.
37. Hinoshita E, Uchiumi T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y et at Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6(6): 2401-2407, 2000.
38. Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M et at The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 5(7): 1800-1806, 2006.
39. Johnson SW, Shen D, Pastan I, Gottesman MM and Hamilton TC: Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res 26(1): 133-139, 1996.
40. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ and Hamilton TC: Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55(19): 4367-4374, 1995.
41. Pawlak-Roblin C, Tosi PF, Perrin L, Devy J, Venteo L, Albert P et al: Inhibition of multidrug rsistance by immunisation with synthetic P-glycoprotein-derived peptides. Eur J Cancer 40(4): 606-613, 2004.
42. Azuma E, Masuda S, Qi J, Kumamoto T, Hirayama M, Nagai M et al: Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias. Eur J Haematol 59(1): 14-19, 1997.
43. Niethammer AG, Wodrich H, Loeffler M, Lode HN, Emmerich K, Abdollahi A et al: Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. FASEB J 19(1): 158-159, 2005.
44. Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S et al: Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 18(11): 6387-6398, 1998.
45. Schmidt J, Jaeger D, Hoffmann K, Buchler MW and Maerten A: Impact of interferon-α in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother 30(1): 108-115, 2007.